- Home
- MGRX vs CURX Comparison
MGRX vs CURX Comparison
Compare MGRX & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGRX | CURX |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 7.9M |
| IPO Year | 2023 | 2024 |
Fundamental Metrics
Financial Performance| Metric | MGRX | CURX |
|---|---|---|
| Price | $0.47 | $4.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 453.2K | 23.7K |
| Earning Date | 11-13-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $456,021.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.26 | $0.18 |
| 52 Week High | $2.75 | $6.80 |
Technical Indicators
Market Signals| Indicator | MGRX | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 64.84 |
| Support Level | $0.34 | $3.91 |
| Resistance Level | $0.48 | $6.00 |
| Average True Range (ATR) | 0.04 | 0.34 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 54.64 | 72.13 |
Price Performance
Historical ComparisonAbout MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.